SERENTIL
LOE ApproachingNDAORALTABLET
Approved
Feb 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERENTIL is an oral small-molecule tablet approved in 1970 by Novartis under NDA designation. The specific indication and mechanism of action are not documented in available data. Patient assignment and therapeutic positioning require additional clinical information.
LOE Approaching
Product approaching loss of exclusivity with modest competitive pressure (30%), suggesting defensive commercial positioning and potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching LOE status indicate limited career growth opportunity on this product. Roles would focus on defensive commercial strategy, pricing optimization, and channel management rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on SERENTIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.